CPT1A and colorectal carcinoma: However, our data demonstrated that the low level of CPT1A in CRC tumors with PM shifted their metabolism to rely more heavily on glycolysis, which implied that CRC cells with PM may be more sensitive to antiangiogenic drugs and glycolysis inhibitors.